Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
Journal of Experimental Medicine · 05.02.2024 · 221 (2)
DOI: 10.1084/jem.20231353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 04.01.2024. Verfasst von Paul Bastard und 59 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIAID NIH HHS, Howard Hughes Medical Institute.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children , Paris, France.
- University Paris Cité, Imagine Institute , Paris, France.
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University , New York, NY, USA.
- Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (AP-HP) , Paris, France.
- Dept. of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Dept. of Pediatrics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
ORCID-Profile: Paul Bastard, Adrian Gervais, Maki Taniguchi, Liisa Saare, Karita Särekannu, Tom Le Voyer, Quentin Philippot, Jérémie Rosain, Lucy Bizien, Takaki Asano, Marina Garcia-Prat, Alba Parra-Martínez, Mélanie Migaud, Miyuki Tsumura, Francesca Conti, Alexandre Belot, Jacques G Rivière, Tomohiro Morio, Junko Tanaka, Etienne Javouhey, Filomeen Haerynck, Sotirija Duvlis, Tayfun Ozcelik, Sevgi Keles, Yacine Tandjaoui-Lambiotte, Simon Escoda, Maya Husain, Qiang Pan-Hammarström, Lennart Hammarström, Gloria Ahlijah, Anthony Abi Haidar, Camille Soudee, Hassan Abolhassani, Sabina Sahanic, Ivan Tancevski, Yoko Nukui, Seiichi Hayakawa, George P Chrousos, Athanasios Michos, Elizabeth-Barbara Tatsi, Filippos Filippatos, Agusti Rodriguez-Palmero, Jesus Troya, Imran Tipu, Isabelle Meyts, Lucie Roussel, Sisse Rye Ostrowski, Laire Schidlowski, Carolina Prando, Antonio Condino-Neto, Nathalie Cheikh, Ahmed A Bousfiha, Jalila El Bakkouri, Pärt Peterson, Aurora Pujol, Romain Lévy
Förderung
- Medical Research Council
- NIAID NIH HHS
- Howard Hughes Medical Institute
- European Research Council
- NIH HHS
- NCATS NIH HHS
Zitieren
APA
Bastard, P., Gervais, A., Taniguchi, M., Saare, L., Särekannu, K., Le Voyer, T., Philippot, Q., Rosain, J., Bizien, L., Asano, T., Garcia-Prat, M., Parra-Martínez, A., Migaud, M., Tsumura, M., Conti, F., Belot, A., Rivière, J. G., Morio, T., Tanaka, J., …, & Lévy, R. (2024). Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children. Journal of Experimental Medicine, 221(2). https://doi.org/10.1084/jem.20231353
Vancouver
Bastard P, Gervais A, Taniguchi M, Saare L, Särekannu K, Le Voyer T, et al. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children. Journal of Experimental Medicine. 2024;221(2). doi:10.1084/jem.20231353
BibTeX
@article{Bastard2024,
author = {Bastard, Paul and Gervais, Adrian and Taniguchi, Maki and Saare, Liisa and Särekannu, Karita and Le Voyer, Tom and Philippot, Quentin and Rosain, Jérémie and Bizien, Lucy and Asano, Takaki and Garcia-Prat, Marina and Parra-Martínez, Alba and Migaud, Mélanie and Tsumura, Miyuki and Conti, Francesca and Belot, Alexandre and Rivière, Jacques G and Morio, Tomohiro and Tanaka, Junko and Javouhey, Etienne and Haerynck, Filomeen and Duvlis, Sotirija and Ozcelik, Tayfun and Keles, Sevgi and Tandjaoui-Lambiotte, Yacine and Escoda, Simon and Husain, Maya and Pan-Hammarström, Qiang and Hammarström, Lennart and Ahlijah, Gloria and Abi Haidar, Anthony and Soudee, Camille and Arseguel, Vincent and Abolhassani, Hassan and Sahanic, Sabina and Tancevski, Ivan and Nukui, Yoko and Hayakawa, Seiichi and Chrousos, George P and Michos, Athanasios and Tatsi, Elizabeth-Barbara and Filippatos, Filippos and Rodriguez-Palmero, Agusti and Troya, Jesus and Tipu, Imran and Meyts, Isabelle and Roussel, Lucie and Ostrowski, Sisse Rye and Schidlowski, Laire and Prando, Carolina and Condino-Neto, Antonio and Cheikh, Nathalie and Bousfiha, Ahmed A and El Bakkouri, Jalila and COVID Clinicians, COVID Clinicians and GEN-COVID Study Group, GEN-COVID Study Group and COVID Human Genetic Effort, COVID Human Genetic Effort and Peterson, Pärt and Pujol, Aurora and Lévy, Romain},
title = {Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children},
journal = {Journal of Experimental Medicine},
year = {2024},
volume = {221},
number = {2},
doi = {10.1084/jem.20231353}
}
EUVIMED